N/A N=150 Intensive Models of HCV Care for Injection Drug Users
Hepatitis C · Medication Adherence
Primary: Electronically Monitored Medication Adherence — 86; 80; 75 Percentage of medication taken
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Ultrasound-guided Peripheral IJ Study
IV Access
Primary: Number of Participants With Successful Cannulation of the Internal Jugular Vein — 34 Participants
N/A N=1,110 Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
Ulcerative Colitis
Primary: Number of Participants Who Experienced at Least One Adverse Events (AEs) — 208 Participants
N/A N=546 A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
Medication Adherence · Substance Abuse, Intravenous · Risk Behavior
Primary: Vaccine Series Completion — 16; 20; 8; 10 participants
N/A N=403 Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
Pneumonia · Pelvic Inflammatory Disease
Primary: Number of Participants With Treatment-Related Adverse Events — 39; 7 Participants
Phase 4 N=480 Immunogenicity of Hepatitis B Vaccination Among Drug Users
Hepatitis B Vaccination
Primary: Number and Rate of Participants With Anti-HBs Seroconversion at Month 7 — 142; 138; 0 Participants
N/A N=99 Loading Vancomycin Doses in the Emergency Department
Infectious Disease
Primary: Percentage of Participants First Achieving Therapeutic Levels at 36 Hours — 20; 18 percentage of participants
Phase 3 N=151 Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
Opioid Use Disorders
Primary: Opioid Use — 6; 12; 7 Participants
N/A N=720 Building on Needle Exchange to Optimize Prevention & Treatment
Intravenous Drug Usage · HIV/AIDS
Primary: Composite PWID Score (Service Access, Risk Behaviors, Adverse Outcomes) — 5.34; 5.64 units on a scale — p=0.125
N/A N=246 Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Hepatitis C, Chronic · Substance Abuse, Intravenous
Primary: Number of Drug-substituted Participants Who Achieved Sustained Virological Response (SVR) With PegIntron 1.5 μg/kg/Week and Rebetol (10.6 mg/kg/Day) in Substitution…
Phase 2 N=1,024 A Network & Dyad HIV Prevention Intervention for IDU's - 1
HIV · Hepatitis
Primary: Any Sex Risk — 48; 62; 119; 179 participants
N/A N=603 Feasibility of Interventions on People Who Inject Drugs in Vietnam
HIV · Hepatitis Virus · Substance Abuse
Primary: Number of Cohort Participants Attending the Last Follow-up Visit at W52 — 194 Participants
Phase 4 N=30 Vapocoolant Spray Used Prior to Intravenous (IV) Insertions
Pain
Primary: Pain Scale Using Visual Analog Scale — 1.13; 1.60 score on a scale
N/A N=755 Patient-Centered Models of HCV Care for People Who Inject Drugs
Hepatitis C · Medication Adherence
Primary: Sustained Viral Response (SVR) — 226; 236 participants
N/A N=243 Optical Detection of Intravenous Infiltration:A Pilot Study
Infiltration of Peripheral IV Therapy
Primary: Time Infiltration Detected by Nurse — 29.8; 32.3 hours
N/A N=95 AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)
Vascular Access Complication
Primary: Percentage of Participants With Successfully Inserted Peripheral IV Catheter Placement on First Attempt — 85.3 percentage of participants
N/A N=594 Reduction in IV Associated Contamination
Post-operative Infections
Primary: Presence of Bacterial IV Stopcock Lumen Contamination — 41; 32 percent stopcock contamination rate
N/A N=982 Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -
Pneumonia · Lung Abscess · Peritonitis
Primary: Number of Participants With Treatment-Related Adverse Events — 96 Participants
N/A N=348 Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Hepatitis C, Chronic
Primary: Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin — 56; 150 participants
Phase 3 N=43 Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection
HIV-1-infection
Primary: Safety of Trogarzo Given as IV Push Over 30 Seconds — 5; 4; 10 Participants
Phase 4 N=215 Titration of Intravenous Hydromorphone
Acute Severe Pain
Primary: Number of Participants Requesting Pain Medication in Different Patterns Over Time — 94; 20; 22; 19 Participants
Phase 4 N=1,054 Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
Bone Infection · Joint Infection
Primary: The Frequency of Definite Failure of Infection Treatment. — 67; 74 Participants
Phase 2 N=44 Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Opioid-Related Disorders
Primary: Emax - Maximum Drug Liking — 54.5; 75.0; 72.1; 75.6 score on a scale
N/A N=304 Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
HIV · Opioid Dependence
Primary: Demonstrated Drug Risk Reduction Skills (0-100%) — 40.60; 42.75 Percentage of correct steps
Phase 4 N=23 Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
Prosthetic Joint Infection · Vancomycin · Joint Diseases
Primary: Systemic Vancomycin Level - Start of Case — 27.98; 0 ug/mL
N/A N=1,004 Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
Staphylococcal Infections
Primary: Number of Participants With Adverse Drug Reaction Not Expected From the Japanese Package Insert. — 1; 1; 1; 1 participants
Phase 4 N=58 Intravenous Fluids in Benign Headaches Trial
Headache
Primary: Reduction in Pain Scores at 60 Minutes — 48.7; 48.3 reduction in visual analog pain score
N/A N=152 Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery
Venous Thrombosis
Primary: Development of DVT (Deep Vein Thrombosis)
Phase 4 N=350 Comparing Intravenous Hydromorphone to Usual Care
Pain
Primary: Number of Participants Who Declined Additional Medication at 30 Minutes — 127; 106 Participants
Phase 4 N=303 Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils
Obstruction · Cancer · Ileus
Primary: Prealbumin — 0.15; 0.16 g/l